Cardiff Oncology Interest Expense 2011-2026 | CRDF

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Cardiff Oncology

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5 K	-39 K	-98 K	-	-	2 K	-	25.4 K	1.03 M	1.67 M	1.53 M	843 K	17 K	-	56.6 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.67 M	-98 K	459 K

Quarterly Interest Expense Cardiff Oncology

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-1 K	7 K	-	5 K	-38 K	-4 K	-	21 K	5 K	-111 K	-	-36 K	-253 K	-49 K	-	3 K	-	-1 K	-	-6 K	6 K	-3 K	-	-	-	-	-	16	925	24.2 K	-	37.1 K	1.57 K	-	-	-	-	-	-	353 K	391 K	390 K	-	390 K	54.7 K	9.5 K	-	6.26 K	668	-	-	-	-	-	-	56.6 K	28.1 K	28.5 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
391 K	-253 K	41.1 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Xeris Pharmaceuticals XERS	-24.3 M	$ 6.03	-1.55 %	$ 885 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
UroGen Pharma Ltd. URGN	-284 K	$ 19.2	-11.52 %	$ 554 M	Israel
uniQure N.V. QURE	10.9 M	$ 10.89	-30.36 %	$ 530 M	Niderland
GT Biopharma GTBP	156 K	$ 0.47	-2.41 %	$ 892 K	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.74	3.6 %	$ 1.12 B	Canada
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	1.26 M	$ 3.36	0.86 %	$ 1.2 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	13.2 M	$ 2.19	-9.77 %	$ 226 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	48 K	$ 4.21	-2.32 %	$ 299 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	7 K	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AbbVie ABBV	2.89 B	$ 233.57	0.64 %	$ 413 B	USA
Blueprint Medicines Corporation BPMC	656 K	-	-	$ 8.14 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AIM ImmunoTech AIM	629 K	$ 0.8	-11.6 %	$ 38.5 M	USA
Apellis Pharmaceuticals APLS	-133 K	$ 20.67	-1.38 %	$ 2.61 B	USA